Daiwa Securities Group’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-650
| Closed | -$2K | – | 1267 |
|
|
2025
Q4 | $2K | Hold |
650
| – | – | ﹤0.01% | 1305 |
|
|
2025
Q3 | $2K | Hold |
650
| – | – | ﹤0.01% | 1266 |
|
|
2025
Q2 | $1K | Hold |
650
| – | – | ﹤0.01% | 1258 |
|
|
2025
Q1 | $1K | Sell |
650
-38,500
| -98% | -$70.9K | ﹤0.01% | 1223 |
|
|
2024
Q4 | $85K | Buy |
39,150
+650
| +2% | +$1.52K | ﹤0.01% | 1006 |
|
|
2024
Q3 | $63K | Hold |
38,500
| – | – | ﹤0.01% | 1044 |
|
|
2024
Q2 | $85K | Hold |
38,500
| – | – | ﹤0.01% | 1039 |
|
|
2024
Q1 | $103K | Hold |
38,500
| – | – | ﹤0.01% | 1046 |
|
|
2023
Q4 | $115K | Sell |
38,500
-235
| -0.6% | -$305 | ﹤0.01% | 997 |
|
|
2023
Q3 | $37K | Hold |
38,735
| – | – | ﹤0.01% | 1078 |
|
|
2023
Q2 | $53K | Hold |
38,735
| – | – | ﹤0.01% | 1071 |
|
|
2023
Q1 | $61K | Hold |
38,735
| – | – | ﹤0.01% | 1033 |
|
|
2022
Q4 | $240K | Sell |
38,735
-25,700
| -40% | -$184K | ﹤0.01% | 919 |
|
|
2022
Q3 | $432K | Hold |
64,435
| – | – | ﹤0.01% | 832 |
|
|
2022
Q2 | $409K | Sell |
64,435
-25,617
| -28% | -$145K | ﹤0.01% | 865 |
|
|
2022
Q1 | $417K | Buy |
90,052
+20,000
| +29% | +$85.8K | ﹤0.01% | 884 |
|
|
2021
Q4 | $350K | Buy |
70,052
+70,000
| +134,615% | +$560K | ﹤0.01% | 915 |
|
|
2021
Q3 | $1K | Hold |
52
| – | – | ﹤0.01% | 1268 |
|
|
2021
Q2 | $1K | Hold |
52
| – | – | ﹤0.01% | 1189 |
|
|
2021
Q1 | $1K | Hold |
52
| – | – | ﹤0.01% | 1195 |
|
|
2020
Q4 | $1K | Sell |
52
-102
| -66% | -$3.06K | ﹤0.01% | 1174 |
|
|
2020
Q3 | $6K | Hold |
154
| – | – | ﹤0.01% | 1073 |
|
|
2020
Q2 | $5K | Hold |
154
| – | – | ﹤0.01% | 1107 |
|
|
2020
Q1 | $5K | Hold |
154
| – | – | ﹤0.01% | 1101 |
|
|
2019
Q4 | $9K | Sell |
154
-17
| -10% | -$764 | ﹤0.01% | 1074 |
|
|
2019
Q3 | $6K | Hold |
171
| – | – | ﹤0.01% | 1064 |
|
|
2019
Q2 | $8K | Hold |
171
| – | – | ﹤0.01% | 1064 |
|
|
2019
Q1 | $7K | Buy |
171
+26
| +18% | +$1.17K | ﹤0.01% | 1053 |
|
|
2018
Q4 | $7K | Hold |
145
| – | – | ﹤0.01% | 1027 |
|
|
2018
Q3 | $6K | Hold |
145
| – | – | ﹤0.01% | 1071 |
|
|
2018
Q2 | $6K | Hold |
145
| – | – | ﹤0.01% | 1083 |
|
|
2018
Q1 | $10K | Buy |
+145
| New | +$10.6K | ﹤0.01% | 1028 |
|
Other funds holding ESPR
WA
TSC
O
Daiwa Securities Group's ESPR Position: Q1 2026 in Review
Daiwa Securities Group sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 650 shares — an estimated $2K sold.
Daiwa Securities Group first reported a position in ESPR in Q1 2018 and held it in 32 quarters. The position peaked at $432K in Q3 2022. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.
- Daiwa Securities Group reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 650 Esperion Therapeutics shares in Q1 2026, an estimated $2K.
- Daiwa Securities Group first reported a position in Esperion Therapeutics in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's Esperion Therapeutics position peaked at $432K in Q3 2022.
- 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.